Evidence map›Paper›PMID 30671229›Full record

ReviewCell regeneration (London, England)2018

Approaches for generation of anti-leukemia specific T cells.

Zhenyi Jin, Ling Xu, Yangqiu Li

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell regeneration (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zhenyi JinKey Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine; Jinan University, Guangzhou, 510632, China.
Ling XuKey Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine; Jinan University, Guangzhou, 510632, China.
Yangqiu LiKey Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine; Jinan University, Guangzhou, 510632, China.
Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As three decades ago, it was reported that adoptive T cell immunotherapy by infusion of autologous tumor infiltrating lymphocytes (TILs) mediated objective cancer regression in patients with metastatic melanoma. A new era of T cell immunotherapy arose since the improvement and clinical use of anti-CD19 chimeric antigen receptor T cells (CAR-T) for the treatment of refractory and relapsed B lymphocyte leukemia. However, several challenges and difficulties remain on the way to reach generic and effective T cell immunotherapy, including lacking a generic method for generating anti-leukemia-specific T cells from every patient. Here, we summarize the current methods of generating anti-leukemia-specific T cells, and the promising approaches in the future.

Indexed as

ACT, adoptive cellular immunotherapyallo-HSCT, allogeneic hematopoietic stem cell transplantationAnti-leukemia T cellAPL, promyelocytic leukemiaB-ALL, cell acute lymphoblastic leukemiaCAR-TCAR-T, chimeric antigen receptor T cellsCML, chronic myelogenous leukemiaCR, complete remissionCTLs, cytotoxic T cellsDLI, donor lymphocyte infusionFLT3-ITD, FLT3 internal tandem duplicationGVHD, graft-versus-host diseaseGVL, graft-versus-leukemiahESC, human embryonic stem cellHLA, human leukocyte antigenHPCs, hematopoietic progenitor cellsIg, immunoglobulinIL-2, interleukin-2iPSCs, induced pluripotent stem cellsiTs, induced functional T cellsscFv, single-chain variable fragmentTAA, tumor-associated antigenT cell immunotherapyT cell reprogrammingTCR-TTCR-T, TCR gene-modified T cellTIL, infiltrating lymphocytesTKI, tyrosine kinase inhibitorWT1, Wilm's tumor antigen 1

Identifiers

PMID30671229
PMCPMC6326242
OpenAlexW2899399093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.